Top

Published in:

01-08-2019 | Solid Tumor | Review Article

Cancer immunotherapy: the art of targeting the tumor immune microenvironment

Authors: Jesse Lopes da Silva, Alexssandra Lima S. Dos Santos, Natalia Cristina Cardoso Nunes, Flora de Moraes Lino da Silva, Carlos Gil Moreira Ferreira, Andreia Cristina de Melo

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2019

Abstract

For many decades, cancer treatment has been strongly directed toward the development of cytotoxic and cytostatic drugs, quite often leading to disappointing results due to the inter- and intra-tumoral heterogeneity. Lately, this intra-cellular look has given way to the understanding of the tumor microenvironment, thus enabling modification of the immunological dynamics between tumor cells and their host. An era of new drugs aiming to unlock the host immune system against tumor cells is steadily increasing. Strategies involving adoptive cell therapy, therapeutic vaccines, immune checkpoint inhibitors and so on have provided spectacular clinical responses and increased survival in previously refractory settings and “hard-to-treat” cancers. Based on a comprehensive search in the main scientific databases, annals of recent renowned oncology congresses and platforms of ongoing trials, the clinical pharmacology characteristics of the main classes of immunotherapeutic agents, as well as the new treatment strategies related to immunotherapy in solid tumors, are carefully discussed throughout this review.

Kamta J, Chaar M, Ande A, Altomare DA, Ait-Oudhia S (2017) Advancing cancer therapy with present and emerging immuno-oncology approaches. Front Oncol 7:64. https://doi.org/10.3389/fonc.2017.00064 CrossRefPubMedPubMedCentral

Stanculeanu DL, Daniela Z, Lazescu A, Bunghez R, Anghel R (2016) Development of new immunotherapy treatments in different cancer types. J Med Life 9(3):240–248PubMedPubMedCentral

Zhang H, Chen J (2018) Current status and future directions of cancer immunotherapy. J Cancer 9(10):1773–1781. https://doi.org/10.7150/jca.24577 CrossRefPubMedPubMedCentral

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331(6024):1565–1570. https://doi.org/10.1126/science.1203486 CrossRefPubMed

Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6(10):715–727. https://doi.org/10.1038/nri1936 CrossRefPubMed

Wirth TC, Kühnel F (2017) Neoantigen targeting—dawn of a new era in cancer immunotherapy? Front Immunol. https://doi.org/10.3389/fimmu.2017.01848 CrossRefPubMedPubMedCentral

Shankaran V, Ikeda H, Bruce AT et al (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832):1107–1111. https://doi.org/10.1038/35074122 CrossRefPubMed

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013 CrossRefPubMed

Turcotte S, Gros A, Hogan K et al (2013) Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol Baltim Md 1950 191(5):2217–2225. https://doi.org/10.4049/jimmunol.1300538 CrossRef

10.

Yeku O, Li X, Brentjens RJ (2017) Adoptive T-cell therapy for solid tumors. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 37:193–204. https://doi.org/10.14694/EDBK_180328 CrossRef

11.

Mayor P, Starbuck K, Zsiros E (2018) Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol 150(2):361–369. https://doi.org/10.1016/j.ygyno.2018.05.024 CrossRefPubMedPubMedCentral

12.

Rosenberg SA, Yang JC, Sherry RM et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin Cancer Res Off J Am Assoc Cancer Res 17(13):4550–4557. https://doi.org/10.1158/1078-0432.CCR-11-0116 CrossRef

13.

Zacharakis N, Chinnasamy H, Black M et al (2018) Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 24(6):724–730. https://doi.org/10.1038/s41591-018-0040-8 CrossRefPubMedPubMedCentral

14.

Stevanović S, Draper LM, Langhan MM et al (2015) Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol Off J Am Soc Clin Oncol 33(14):1543–1550. https://doi.org/10.1200/JCO.2014.58.9093 CrossRef

15.

Weng NP, Levine BL, June CH, Hodes RJ (1996) Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med 183(6):2471–2479. https://doi.org/10.1084/jem.183.6.2471 CrossRefPubMed

16.

Zhou J, Shen X, Hodes RJ, Rosenberg SA, Robbins PF (2015) Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol Baltim Md 1950 175(10):7046–7052

17.

Powell DJ, Dudley ME, Robbins PF, Rosenberg SA (2005) Transition of late-stage effector T cells to CD27 + CD28 + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105(1):241–250. https://doi.org/10.1182/blood-2004-06-2482 CrossRefPubMed

18.

Huang J, Kerstann KW, Ahmadzadeh M et al (2006) Modulation by IL-2 of CD70 and CD27 expression on CD8 + T Cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol Baltim Md 1950 176(12):7726–7735

19.

Gattinoni L, Klebanoff CA, Restifo NP (2012) Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 12(10):671–684. https://doi.org/10.1038/nrc3322 CrossRefPubMedPubMedCentral

20.

Schmidts A, Maus MV (2018) Making CAR T cells a solid option for solid tumors. Front Immunol. https://doi.org/10.3389/fimmu.2018.02593 CrossRefPubMedPubMedCentral

21.

Besser MJ, Shapira-Frommer R, Treves AJ et al (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res Off J Am Assoc Cancer Res 16(9):2646–2655. https://doi.org/10.1158/1078-0432.CCR-10-0041 CrossRef

22.

Jindal V, Arora E, Gupta S (2018) Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors. Medical Oncology 35(6):87CrossRefPubMed

23.

Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843–851. https://doi.org/10.1038/mt.2010.24 CrossRefPubMedPubMedCentral

24.

Walker AJ, Majzner RG, Zhang L et al (2017) Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol Ther J Am Soc Gene Ther 25(9):2189–2201. https://doi.org/10.1016/j.ymthe.2017.06.008 CrossRef

25.

Scarfò I, Maus MV (2017) Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer 5:28. https://doi.org/10.1186/s40425-017-0230-9 CrossRefPubMedPubMedCentral

26.

Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM (2011) Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol CVI 18(1):23–34. https://doi.org/10.1128/CVI.00286-10 CrossRefPubMed

27.

Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422. https://doi.org/10.1056/NEJMoa1001294 CrossRefPubMed

28.

Rieger CT, Liss B, Mellinghoff S et al (2018) Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Oncol 29(6):1354–1365. https://doi.org/10.1093/annonc/mdy117 CrossRefPubMedPubMedCentral

29.

Guo Y, Lei K, Tang L (2018) Neoantigen vaccine delivery for personalized anticancer immunotherapy. Front Immunol 9:1499. https://doi.org/10.3389/fimmu.2018.01499 CrossRefPubMedPubMedCentral

30.

Hobo W, Strobbe L, Maas F et al (2013) Immunogenicity of dendritic cells pulsed with MAGE3, survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother CII 62(8):1381–1392. https://doi.org/10.1007/s00262-013-1438-2 CrossRefPubMed

31.

Gibney GT, Kudchadkar RR, DeConti RC et al (2015) Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res 21(4):712–720. https://doi.org/10.1158/1078-0432.CCR-14-2468 CrossRef

32.

Bai J, Gao Z, Li X, Dong L, Han W, Nie J (2017) Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. Oncotarget 8(66):110693–110707. https://doi.org/10.18632/oncotarget.22690 CrossRefPubMedPubMedCentral

33.

Vermaelen K, Waeytens A, Kholmanskikh O, den B Van M, Van EV (2018) Perspectives on the integration of immuno-oncology biomarkers and drugs in a health care setting. Semin Cancer Biol 52(Pt 2):166–177. https://doi.org/10.1016/j.semcancer.2017.11.011 CrossRefPubMed

34.

Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways. Am J Clin Oncol 39(1):98–106. https://doi.org/10.1097/COC.0000000000000239 CrossRefPubMedPubMedCentral

35.

Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol 33(17):1974–1982. https://doi.org/10.1200/JCO.2014.59.4358 CrossRef

36.

Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4):450–461. https://doi.org/10.1016/j.ccell.2015.03.001 CrossRefPubMedPubMedCentral

37.

Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. https://doi.org/10.3389/fonc.2018.00086 CrossRefPubMedPubMedCentral

38.

Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:49. https://doi.org/10.3389/fphar.2017.00049 CrossRefPubMedPubMedCentral

39.

Hodi FS, Ballinger M, Lyons B et al (2018) Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol Off J Am Soc Clin Oncol 36(9):850–858. https://doi.org/10.1200/JCO.2017.75.1644 CrossRef

40.

Hodi FS, Hwu W-J, Kefford R et al (2016) Evaluation of immune-related response criteria and RECIST v 1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol Off J Am Soc Clin Oncol 34(13):1510–1517. https://doi.org/10.1200/jco.2015.64.0391 CrossRef

41.

Nishino M, Giobbie-Hurder A, Manos MP et al (2017) Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions. Clin Cancer Res Off J Am Assoc Cancer Res 23(16):4671–4679. https://doi.org/10.1158/1078-0432.CCR-17-0114 CrossRef

42.

Larkin J, Gore M. Malignant melanoma (metastatic). BMJ Clin Evid. 2008;2008. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907961/. Accessed 17 May 2019

43.

Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. https://doi.org/10.1056/NEJMoa1003466 CrossRefPubMedPubMedCentral

44.

Eggermont AM, Chiarion-Sileni V, Grob JJ et al (2016) Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med 375(19):1845–1855. https://doi.org/10.1056/NEJMoa1611299 CrossRefPubMedPubMedCentral

45.

Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532. https://doi.org/10.1056/NEJMoa1503093 CrossRefPubMed

46.

Wan MT, Ming ME (2018) Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal. Br J Dermatol 179(2):296–300. https://doi.org/10.1111/bjd.16785 CrossRefPubMed

47.

Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006–2017. https://doi.org/10.1056/NEJMoa1414428 CrossRefPubMedPubMedCentral

48.

Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290. https://doi.org/10.1056/NEJMoa1712126 CrossRefPubMedPubMedCentral

49.

Ribas A, Kefford R, Marshall MA et al (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31(5):616–622. https://doi.org/10.1200/JCO.2012.44.6112 CrossRefPubMedPubMedCentral

50.

Rini BI, Stein M, Shannon P et al (2011) Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117(4):758–767. https://doi.org/10.1002/cncr.25639 CrossRefPubMed

51.

Chung KY, Gore I, Fong L et al (2010) Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(21):3485–3490. https://doi.org/10.1200/JCO.2010.28.3994 CrossRef

52.

Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627 CrossRefPubMedPubMedCentral

53.

Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III Or IV melanoma. N Engl J Med 377(19):1824–1835. https://doi.org/10.1056/NEJMoa1709030 CrossRefPubMed

54.

Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. https://doi.org/10.1056/NEJMoa1510665 CrossRefPubMedPubMedCentral

55.

Ferris RL, Blumenschein G, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867. https://doi.org/10.1056/NEJMoa1602252 CrossRefPubMedPubMedCentral

56.

Sharma P, Retz M, Siefker-Radtke A et al (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CHECKMATE-275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3):312–322. https://doi.org/10.1016/S1470-2045(17)30065-7 CrossRefPubMed

57.

Overman MJ, McDermott R, Leach JL et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CHECKMATE-142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182–1191. https://doi.org/10.1016/S1470-2045(17)30422-9 CrossRefPubMedPubMedCentral

58.

El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CHECKMATE-040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet Lond Engl 389(10088):2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2 CrossRef

59.

Schachter J, Ribas A, Long GV et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet Lond Engl 390(10105):1853–1862. https://doi.org/10.1016/S0140-6736(17)31601-X CrossRef

60.

Reck M, Rodríguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with Pd-L1 tumor proportion score of 50% or greater. J Clin Oncol Off J Am Soc Clin Oncol 37(7):537–546. https://doi.org/10.1200/JCO.18.00149 CrossRef

61.

Mok TSK, Wu Y-L, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet Lond Engl 393(10183):1819–1830. https://doi.org/10.1016/S0140-6736(18)32409-7 CrossRef

62.

Langer CJ, Gadgeel SM, Borghaei H et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17(11):1497–1508. https://doi.org/10.1016/S1470-2045(16)30498-3 CrossRefPubMedPubMedCentral

63.

Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078–2092. https://doi.org/10.1056/NEJMoa1801005 CrossRefPubMed

64.

Paz-Ares L, Luft A, Vicente D et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379(21):2040–2051. https://doi.org/10.1056/NEJMoa1810865 CrossRefPubMed

65.

Plimack ER, Bellmunt J, Gupta S et al (2017) Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 18(2):212–220. https://doi.org/10.1016/S1470-2045(17)30007-4 CrossRefPubMed

66.

Balar AV, Castellano D, O’Donnell PH et al (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(11):1483–1492. https://doi.org/10.1016/S1470-2045(17)30616-2 CrossRefPubMed

67.

Schellens JHM, Marabelle A, Zeigenfuss S et al. Pembrolizumab for previously treated advanced cervical squamous cell cancer: preliminary results from the phase 2 KEYNOTE-158 study. J Clin Oncol. https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.5514. Accessed 21 May 2019

68.

Fuchs CS, Doi T, Jang RW et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4(5):e180013. https://doi.org/10.1001/jamaoncol.2018.0013 CrossRefPubMedPubMedCentral

69.

Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520. https://doi.org/10.1056/NEJMoa1500596 CrossRefPubMedPubMedCentral

70.

Zhang L, Peng Y, Peng G (2018) Mismatch repair-based stratification for immune checkpoint blockade therapy. Am J Cancer Res 8(10):1977–1988PubMedPubMedCentral

71.

Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet Lond Engl 389(10066):255–265. https://doi.org/10.1016/S0140-6736(16)32517-X CrossRef

72.

Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288–2301. https://doi.org/10.1056/NEJMoa1716948 CrossRefPubMed

73.

Petrylak DP, Powles T, Bellmunt J et al (2018) Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: long-term outcomes from a phase 1 study. JAMA Oncol 4(4):537–544. https://doi.org/10.1001/jamaoncol.2017.5440 CrossRefPubMedPubMedCentral

74.

Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet Lond Engl 387(10031):1909–1920. https://doi.org/10.1016/S0140-6736(16)00561-4 CrossRef

75.

Powles T, Durán I, van der Heijden MS et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Lond Engl 391(10122):748–757. https://doi.org/10.1016/S0140-6736(17)33297-X CrossRef

76.

Balar AV, Galsky MD, Rosenberg JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet Lond Engl 389(10064):67–76. https://doi.org/10.1016/S0140-6736(16)32455-2 CrossRef

77.

Patel MR, Ellerton J, Infante JR et al (2018) Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 19(1):51–64. https://doi.org/10.1016/S1470-2045(17)30900-2 CrossRefPubMed

78.

D’Angelo SP, Russell J, Lebbé C et al (2018) Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol 4(9):e180077. https://doi.org/10.1001/jamaoncol.2018.0077 CrossRefPubMedPubMedCentral

79.

Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380(12):1103–1115. https://doi.org/10.1056/NEJMoa1816047.CrossRefPubMedPubMedCentral

80.

Lee NY, Ferris RL, Beck JT et al. Study to compare avelumab in combination with standard of care chemoradiotherapy (SoC CRT) versus SoC CRT for definitive treatment in patients with locally advanced squamous cell carcinoma of the head and neck (JAVELIN head and neck 100). https://clinicaltrials.gov/ct2/show/NCT02952586. Accessed 21 May 2019

81.

Safety and efficacy study of avelumab plus chemotherapy with or without other anti-cancer immunotherapy agents in patients with advanced malignancies-NCT03317496. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2018-00236 Published February 2, 2011. Accessed 21 May 2019

82.

A study of avelumab in combination with other cancer immunotherapies in advanced malignancies (JAVELIN medley)-NCT02554812. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2015-02263 Published February 2, 2011. Accessed 21 May 2019

83.

Powles T, O'Donnell PH, Massard C et al (2017) Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 3(9):e172411. https://doi.org/10.1001/jamaoncol.2017.2411 CrossRefPubMedPubMedCentral

84.

Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919–1929. https://doi.org/10.1056/NEJMoa1709937 CrossRefPubMed

85.

Katz JB1, Muller AJ, Prendergast G. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. https://www.ncbi.nlm.nih.gov/pubmed/18364004. Accessed 21 May 2019

86.

Mitchell TC, Hamid O, Smith DC et al (2018) Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J Clin Oncol Off J Am Soc Clin Oncol. https://doi.org/10.1200/jco.2018.78.9602 CrossRef

87.

Long GV, Dummer R, Hamid O et al (2018) Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301/KEYNOTE-252 study. J Clin Oncol 36(15_suppl):108. https://doi.org/10.1200/jco.2018.36.15_suppl.108 CrossRef

88.

Daud A, Saleh MN, Hu J et al (2018) Epacadostat plus nivolumab for advanced melanoma: updated phase 2 results of the ECHO-204 study. J Clin Oncol 36(15_suppl):9511. https://doi.org/10.1200/jco.2018.36.15_suppl.9511 CrossRef

89.

Smith DC, Gajewski T, Hamid O et al. Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: preliminary phase I/II results of ECHO-202/KEYNOTE-037. J Clin Oncol. https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4503. Accessed 21 May 2019

90.

Zakharia Y, Rixe O, Ward JH et al (2018) Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma. J Clin Oncol 36(15_suppl):9512. https://doi.org/10.1200/jco.2018.36.15_suppl.9512 CrossRef

91.

Maleki Vareki S, Garrigós C, Duran I (2017) Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol 116:116–124. https://doi.org/10.1016/j.critrevonc.2017.06.001 CrossRefPubMed

92.

Albacker LA, Wu J, Smith P et al (2017) Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS One 12(11):e0176181. https://doi.org/10.1371/journal.pone.0176181 CrossRefPubMedPubMedCentral

93.

Chowell D, Morris LGT, Grigg CM et al (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359(6375):582–587. https://doi.org/10.1126/science.aao4572 CrossRefPubMed

94.

Lopez A, Hansmannel F, Kokten T et al (2017) Microbiota in digestive cancers: our new partner? Carcinogenesis 38(12):1157–1166. https://doi.org/10.1093/carcin/bgx087 CrossRefPubMed

95.

Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97–103. https://doi.org/10.1126/science.aan4236 CrossRefPubMed

96.

Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774 CrossRefPubMed

97.

Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: open-label, phase 3 KEYNOTE-042 study. J Clin Oncol. https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.18_suppl.LBA4. Accessed 24 May 2019

98.

Seiwert TY, Burtness B, Mehra R et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956–965. https://doi.org/10.1016/S1470-2045(16)30066-3 CrossRefPubMed

99.

Frenel J-S, Le Tourneau C, O’Neil B et al (2017) Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol Off J Am Soc Clin Oncol 35(36):4035–4041. https://doi.org/10.1200/JCO.2017.74.5471 CrossRef

Title: Cancer immunotherapy: the art of targeting the tumor immune microenvironment
Authors: Jesse Lopes da Silva
Alexssandra Lima S. Dos Santos
Natalia Cristina Cardoso Nunes
Flora de Moraes Lino da Silva
Carlos Gil Moreira Ferreira
Andreia Cristina de Melo
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Keywords: Solid Tumor
Melanoma
Melanoma
Urothelial Cancer
Urothelial Cancer
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03894-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Phase I study of BGT226, a pan-PI3K and mTOR inhibitor, in Japanese patients with advanced solid cancers

An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine

MSI2-TGF-β/TGF-β R1/SMAD3 positive feedback regulation in glioblastoma

Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer

Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations

A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer